|
2024
|
Invention
|
Ether linked triazoles as nrf2 activators.
The present invention relates to ether-linked triazol... |
|
|
Invention
|
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity.
The invention p... |
|
2023
|
Invention
|
Bicyclic heterocycle compounds and their uses in therapy.
The invention relates to bicyclic hete... |
|
|
Invention
|
Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-... |
|
2022
|
Invention
|
Pyrrolopyrimidine compounds and their uses.
The disclosed compounds relate to treatments and the... |
|
|
Invention
|
Bicyclic heterocycle compounds and their uses in therapy. The invention relates to new bicyclic h... |
|
|
Invention
|
Small molecule inhibitors of kras mutated proteins. Compounds of Formula (I) or their pharmaceuti... |
|
|
Invention
|
Small molecule inhibitors of kras mutated proteins.
Compounds of Formula (I) or their pharmaceut... |
|
2021
|
Invention
|
Pyrazolyl quinoxaline kinase inhibitors.
The invention relates to new quinoxaline derivative com... |
|
|
Invention
|
Nrf2 regulators.
The present invention relates to aryl analogs, pharmaceutical compositions cont... |
|
|
Invention
|
Ether linked triazoles as nrf2 activators. The present invention relates to ether-linked triazole... |
|
|
Invention
|
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl... |
|
2020
|
Invention
|
Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n′-(1-methylethyl)-n-[3-(1-methyl-... |
|
|
Invention
|
A compound having inhibitory activity against kras g12d mutation. The present invention relates t... |
|
|
Invention
|
4-aminobut-2-enamide derivatives and salts thereof.
The present invention provides an antitumor ... |
|
|
Invention
|
4-aminobut-2-enamide derivatives and salts thereof. The present invention provides an antitumor a... |
|
|
Invention
|
Bicyclic heterocycle compounds and their uses in therapy. The invention relates to bicyclic heter... |
|
|
Invention
|
Combination of an fgfr inhibitor and a cmet inhibitor. The invention relates to a combination of ... |
|
2019
|
Invention
|
Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity. The invention pr... |
|
|
Invention
|
Indanes as nrf2 activators. The present invention relates to indane compounds, methods of making ... |
|
|
Invention
|
Nrf2 regulators. The present invention relates to aryl analogs, pharmaceutical compositions conta... |
|
2018
|
Invention
|
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and mu... |
|
|
Invention
|
Nrf2 regulators.
The present invention relates to bis aryl analogs, pharmaceutical compositions ... |
|
|
Invention
|
Combinations. The invention relates to a combination of a first compound selected from N-(3,5-dim... |
|
|
Invention
|
Pharmaceutical compounds. The invention provides a combination comprising: (i) a compound of form... |
|
|
Invention
|
Combination of isoindolinone derivatives with sgi-110. The invention provides a combination compr... |
|
|
Invention
|
Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them. The invention r... |
|
2017
|
Invention
|
Quinoxaline derivatives useful as fgfr kinase modulators. The invention relates to new quinoxalin... |
|
|
Invention
|
Bisaryl lactams as nrf2 activators.
The present invention relates to bisaryl lactam compounds, m... |
|
|
Invention
|
N-aryl pyrazoles as nrf2 regulators.
The present invention relates to N-aryl pyrazole compounds,... |
|
|
Invention
|
Bisaryl heterocycles as nrf2 activators. The present invention relates to bisaryl heterocycle com... |
|
|
Invention
|
Bisaryl amides as nrf2 activators. The present invention relates to bisaryl amide analogs, pharma... |
|
2016
|
Invention
|
Arylcyclohexyl pyrazoles as nrf2 regulators. The present invention relates to arylcyclohexyl pyra... |
|
|
Invention
|
Biaryl pyrazoles as nrf2 regulators. The present invention relates to biaryl pyrazole compounds o... |
|
|
Invention
|
Nrf2 regulators. Provided are aryl analogs, pharmaceutical compositions containing them and their... |
|
2015
|
P/S
|
Pharmaceuticals, namely, pharmaceutical preparations for the diagnosis or treatment of diseases a... |
|
2012
|
P/S
|
Chemicals, chemical compounds and chemical preparations for non-medical purposes, namely, those ... |
|
|
P/S
|
Chemicals, chemical compounds and chemical preparations and products including those for use in b... |
|
|
P/S
|
Chemicals, chemical compounds and chemical preparations and
products including those for use in ... |
|
|
P/S
|
Chemicals, chemical compounds and chemical preparations for non-medical purposes, namely, those f... |
|
2011
|
P/S
|
Providing health care information via the Internet |
|
|
P/S
|
Computer software for the manipulation and presentation of data for use in relation to drug disco... |
|
|
P/S
|
Research and development services in the field of pharmaceuticals; providing medical and scientif... |
|
|
P/S
|
Research and development services in the field of
pharmaceuticals; providing medical and scienti... |
|
2005
|
P/S
|
Chemicals, chemical compounds and products, including those for use in biotechnology, drug discov... |
|
2000
|
P/S
|
Drug discovery services; biotechnology research [ Computer software for manipulation and presenta... |
|
|
P/S
|
Computer software for use in relation to drug discovery; computer software for use in relation to... |
|
|
P/S
|
Pharmaceuticals. Computer software for use in relation to drug discovery; computer software for u... |
